$INCY

Tray Thomas sold $200K of INCY

Tray Thomas (Principal Accounting Officer) sold 2,051 shares of INCYTE CORP (INCY) at $97.35 ($0.20M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tray Thomas
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INCY
Neutral
medium confidence
Mentioned
$INCY
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price, and post-transaction holdings under a 10b5-1 plan; it does not include guidance, litigation, or operational updates.

02

Market read

Traders may note the insider sale as a sentiment datapoint, but the 10b5-1 structure makes it unlikely to drive a durable repricing by itself.

03

What to watch

Insider sales can be offset by other insider buys or option exercises not shown here; also, the filing does not reveal intent beyond the pre-arranged plan.

Relevance 3/10Novelty 3/10Timing: filed 2026-05-28, transaction dated 2026-05-26

Background

This is an SEC Form 4 insider transaction disclosure for Incyte, reported by Tray Thomas (Principal Accounting Officer).

Company-level read

Ticker impact

$INCYNeutralMedium confidence
Context

Incyte Form 4 shows Tray Thomas sold 2,051 shares at $97.35 on a 10b5-1 plan, disclosing $199,664.85 in insider sales.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other new fundamentals.

Evidence & confidence

The filing is a primary-source Form 4 and is time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity-driven under the 10b5-1 schedule and should not be treated as bearish signal.

Key entities

  • Incyte Corp

    Subject of the Form 4 insider transaction disclosure.

  • Tray Thomas

    Principal Accounting Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INCYHigh

Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks

Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (INCY) and Biogen (BIIB) as top stock picks, focusing on healthcare over AI. Incyte's stock is up 22% this year, with strong earnings and a growing drug pipeline. The company reported 38% revenue growth and raised its 2026 sales guidance. Risks include Jakafi's patent expiration and competition for Opzelura.

$INCYHighAI 9/10

Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?

Incyte (INCY) and Revolution Medicines (RVMD) are competing in the KRAS inhibitor market. RBC noted INCY's upcoming ESMO data for its KRAS G12D inhibitor, while Bernstein raised RVMD's price target. RVMD received FDA approval for Rasonque. INCY reported Q2 2026 revenue of $1.67B, while RVMD had no product revenue but $3.9B in cash. Institutional investors favor RVMD, with notable holdings by Farallon Capital and Baker Bros. Advisors.

$INCYHighAI 8/10

How Q2 Beat, Opzelura Demand and Niktimvo Approval At Incyte (INCY) Has Changed Its Investment Story

Incyte (INCY) reported Q2 2026 earnings and revenue above expectations, driven by strong demand for Jakafi and Opzelura. The company raised its 2026 net product revenue guidance and received FDA approval for Niktimvo, adding a new therapy to its portfolio. Analysts project varying revenue and earnings estimates for 2029, with the company targeting $5.8 billion in revenue and $1.1 billion in earnings, while the lowest estimates predict $5.4 billion in revenue and $1.2 billion in earnings.

$INCYHighAI 8/10

Incyte Stock: Is Wall Street Bullish or Bearish?

Incyte (INCY) raised its 2026 revenue forecast to $5.13B-$5.26B after a CMS settlement. Q2 2026 net sales rose 40% to $1.49B, and adjusted EPS was $3.09, beating estimates. Analysts expect FY 2026 EPS to decrease 52.7% YoY to $2.64. The stock has a 'Moderate Buy' consensus rating, with a mean price target of $127.09.